$AEHR

AEHR TEST SYSTEMS (AEHR) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. The Annual Meeting of shareholders of Aehr Test Systems (the “Company”) was held on October 19, 2026 (the “Annual Meeting”). There were 32,659,546 shares of common stock entitled to vote at the Annual Meeting and 22,

Aehr Test Systems (NASDAQ: AEHR) will report its first quarter fiscal 2027 results on November 2, 2026. The company, which provides test solutions for semiconductor devices, will host a conference call and webcast to discuss the results. Aehr changed its fiscal year end from May to June, with the first quarter of fiscal 2027 ending on September 25, 2026.

Aehr Test Systems (AEHR) received $6M in follow-on orders from a hyperscale customer for AI processor test and burn-in solutions. The order includes Sonoma systems, BIMs, and software enhancements, with deliveries over six months. The customer expects this AI processor's production volume to exceed its first processor, already in high-volume production.

Aehr Test Systems (AEHR) is set to report earnings on Oct 6, 2026, with consensus EPS at $0.10 and revenue at $26.82M. The company's stock has surged 405% YTD, trading at $106.34. Analysts expect revenue growth due to AI demand and memory testing potential, but caution that the stock may be priced for perfection.

Aehr Test Systems (AEHR) shares rose 5.5% to $107.21 on October 2, 2026, with a 52-week range of $18.70 to $147.40. GF Value™ estimates AEHR is 409.8% overvalued, with a GF Value of $21.03. Insiders sold $62.7M in shares over the past year, and the company is unprofitable and cash-flow negative. AEHR's GF Score™ is 67/100, indicating above-average valuation quality but concerns about profitability and valuation.

Aehr Test Systems (AEHR) stock rose 7.06% on strong semiconductor test demand and AI-driven growth prospects. Oppenheimer initiated an Outperform rating with a $120 target, citing a $41M hyperscaler order. AEHR reported $18.8M revenue, $1.39M net income, and a strong balance sheet. The stock has gained 32% in a month, driven by AI and EV themes.

Wall Street analysts expect three chip companies to triple revenue. Lumentum (LITE) forecasts $13.7B by 2029, driven by AI data center demand. Aehr Test Systems (AEHR) projects $271M by 2029, fueled by AI chip testing. Navitas Semiconductor (NVTS) anticipates $200M by 2029, pivoting to AI infrastructure. Growth depends on customer orders, product launches, and market demand.

Aehr Test Systems (AEHR) stock falls 7.5% in morning trading, extending a decline from September 22. The drop follows a Zacks Research downgrade to 'hold' and recent insider selling. Analysts have mixed views, with Oppenheimer and Jefferies issuing positive ratings. The stock trades near $93.05, well below its 52-week high of $147.40, amid a broader market decline.

Analysts initiated coverage on five companies: Goldman Sachs rated Abivax Buy with $155 PT, BTIG rated Amer Sports Buy with $42 PT, Morgan Stanley rated Coinbase Equal-Weight with $250 PT, Oppenheimer rated Aehr Test Outperform with $120 PT, and Piper Sandler rated Intel Neutral with $110 PT. All companies closed below their respective targets on Wednesday.

Analysts made several calls on Thursday, including Truist initiating Nebius with a Buy rating and $355 price target, Deutsche Bank initiating Clover Health with a Buy rating and $6 target, and Wells Fargo upgrading Synopsys and Yum Brands. Morgan Stanley initiated Revolution Medicine and upgraded TC Energy and DT Midstream. JPMorgan upgraded Meta to Overweight with an $820 target and reiterated Tesla as Neutral.